| Literature DB >> 29988642 |
Takashi Hongo1, Midori Tsuchiya1, Mototaka Inaba1, Kenji Takahashi1, Satoshi Nozaki1, Toshifumi Fujiwara1, Makoto Hiramatsu2.
Abstract
AIM: We aimed to examine the relationship between kidney size and contrast-induced nephropathy (CIN) in patients who underwent contrast-enhanced computed tomography (CT) in the emergency department.Entities:
Keywords: Contrast‐induced nephropathy; emergency department; kidney size; renal thickness
Year: 2018 PMID: 29988642 PMCID: PMC6028793 DOI: 10.1002/ams2.346
Source DB: PubMed Journal: Acute Med Surg ISSN: 2052-8817
Figure 1Kidney size was measured manually in patients who underwent contrast‐enhanced computed tomography in the emergency department, using the distance between computed tomography images in the slice of the renal vein. Renal depth (red arrows) was measured as the distance from the renal hilum to the opposite side on the transverse plane. Renal width (left panel, yellow arrow) was measured as the longest distance on an axis perpendicular to the renal width on the transverse plane. Renal thickness (right panel, green arrows) was measured as the straight distance from the renal calyx to the opposite side on the transverse plane.
Figure 2Flowcharts of patients with contrast‐induced nephropathy (CIN) or no CIN who underwent contrast‐enhanced computed tomography in the emergency department.
Characteristics of patients who underwent contrast‐enhanced computed tomography in the emergency department (n = 262)
| CIN negative ( | CIN positive ( |
| |
|---|---|---|---|
| Male gender, | 142/236 | 14/26 | 0.536 |
| Age, years | 71 (61–81) | 73.5 (60–83.5) | 0.350 |
| Height, cm | 160 (152–166) | 162.5 (150–165) | 0.828 |
| Weight, kg | 52.0 (44.1–61.6) | 52.3 (47.3–71.8) | 0.259 |
| Body mass index | 20.6 (18.6–23.6) | 23.2 (19.1–25.1) | 0.144 |
| Prognostic nutritional index | 43.8 (37.3–49.7) | 44.23 (38.4–50.6) | 0.566 |
| Nephrotoxic drugs, | 114/236 | 18/26 | 0.061 |
| Hypertension, | 86/236 | 15/26 | 0.054 |
| Diabetes, | 37/236 | 5/26 | 0.582 |
| CVD, | 35/236 | 5/26 | 0.566 |
| CHF, | 58/236 | 10/26 | 0.156 |
| Cancer, | 55/236 | 2/26 | 0.080 |
| CKD, | 78/236 | 8/26 | 1.000 |
| Purpose of contrast‐enhanced CT | |||
| Gastrointestinal disease, | 162/236 | 16/26 | 0.509 |
| Cardiovascular disease, | 13/236 | 2/26 | 0.650 |
| Lung disease, | 8/236 | 2/26 | 0.260 |
| Brain disease, | 12/236 | 3/26 | 0.176 |
| Infection, | 10/236 | 2/26 | 0.338 |
| Trauma, | 23/236 | 1/26 | 0.485 |
| Others, | 8/236 | 0/26 | 1.000 |
| Dose of contrast medium, mL | 100 (100–135) | 100 (100–100) | 0.314 |
| Total protein, g/dL | 6.7 (6.1–7.1) | 6.6 (6.3–6.9) | 0.893 |
| Albumin, g/dL | 3.7 (3.2–4.2) | 3.6 (3.1–4.2) | 0.695 |
| White blood cells, μL | 9,735 (6,912–12,527) | 9,695 (8,570–13,422) | 0.433 |
| Hemoglobin, g/dL | 12.2 (10.4–13.9) | 12.9 (11.0–13.8) | 0.414 |
| Platelets, 104/μL | 20.8 (15.9–25.9) | 21.1 (15.9–26.3) | 0.860 |
| C‐reactive protein test, mg/dL | 0.76 (0.08–5.74) | 0.78 (0.15–6.66) | 0.874 |
| BUN, mg/dL | 16.8 (12.6–22.2) | 16.5 (11.9–22.4) | 0.764 |
| Serum creatinine, mg/dL | 0.74 (0.60–0.93) | 0.69 (0.52–0.84) | 0.208 |
| eGFR, mL/min | 71.5 (59.0–88.7) | 77.7 (57.5–99.7) | 0.409 |
| Creatinine clearance, mL/min | 36.7 (24.6–53.5) | 35.4 (25.4–49.2) | 0.690 |
| Shock vitals on admission | 18/236 | 2/26 | 1.000 |
| Depth, cm | 4.95 (4.63–5.54) | 4.79 (4.27–5.09) | 0.020 |
| Width, cm | 4.79 (4.46–5.19) | 4.98 (4.16–5.19) | 0.393 |
| Length, cm | 10.7 (10.0–11.2) | 10.2 (9.75–10.50) | 0.007 |
| Thickness, cm | 2.03 (1.86–2.23) | 1.75 (1.56–1.91) | <0.001 |
| Renal volume, cm3 | 130.1 (115.2–152.4) | 125.8 (100.5–144.2) | 0.045 |
| TPA, cm2/m2 | 3.45 (2.77–4.13) | 2.60 (2.04–3.69) | 0.009 |
| KDIGO | |||
| Stage 1 | 0/236 | 23/26 | |
| Stage 2 | 0/236 | 3/26 | |
| Stage 3 | 0/236 | 0/26 | |
Continuous variables are presented as median and interquartile range values. Categorical variables are shown as frequencies or percentages.
P‐values were calculated using Fisher's exact probability test or Mann–Whitney U‐test. Acute kidney injury was defined according to the Acute Kidney Injury Network/Kidney Disease: Improving Global Outcomes (KDIGO) guidelines: stage 1, absolute increase in serum creatinine (sCr) level ≥0.3 mg/dL or a 1.5–1.9‐fold increase over the baseline sCr level; stage 2, 2.0–2.9‐fold increase over the baseline sCr level; and stage 3, 3.0‐fold increase over the baseline sCr level, increase in sCr level ≥4.0 mg/dL, or initiation of dialysis.
BUN, blood urea nitrogen; CIN, contrast‐induced nephropathy; CHF, congestive heart failure; CKD, chronic kidney disease; CVD, cerebrovascular disease; eGFR, estimated glomerular filtration rate; TPA, average of the cross‐sectional area of each psoas muscle.
Multiple logistic regression analysis of risk factors for contrast‐induced nephropathy
| Risk factor | Multivariate analysis | ||
|---|---|---|---|
| OR | 95% CI |
| |
| TPA | 1.00 | 0.98–1.02 | 0.988 |
| Renal volume | 0.88 | 0.59–1.32 | 0.553 |
| Renal thickness | 0.65 | 0.53–0.81 | <0.001 |
CI, confidence interval; OR, odds ratio; TPA, average of the cross‐sectional area of each psoas muscle.
Figure 3Receiver operating characteristic curves of renal thickness in 262 patients who underwent contrast‐enhanced computed tomography in the emergency department. The cut‐off value for renal thickness was 1.83 cm, at which the sensitivity and specificity were 79% and 65%, respectively. The area under the curve for renal thickness was 0.79 (95% confidence interval, 0.701–0.877).
Figure 4Ninety‐day survival curve for renal function in patients who underwent contrast‐enhanced computed tomography in the emergency department and developed contrast‐induced nephropathy. All patients recovered baseline renal function. No patient needed renal replacement therapy.